CRISPR Therapeutics CRSP Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's net change in cash?
- CRISPR Therapeutics (CRSP) reported net change in cash of $72.24M in Q1 2026.
- How has CRISPR Therapeutics's net change in cash changed year-over-year?
- CRISPR Therapeutics's net change in cash increased by 214.5% year-over-year, from -$63.07M to $72.24M.
- What is the long-term trend for CRISPR Therapeutics's net change in cash?
- Over 2 years (2021 to 2025), CRISPR Therapeutics's net change in cash has grown at a -55.2% compound annual growth rate (CAGR), from -$245.52M to $49.3M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.